Matches in SemOpenAlex for { <https://semopenalex.org/work/W2528090440> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2528090440 endingPage "E198" @default.
- W2528090440 startingPage "E198" @default.
- W2528090440 abstract "Local regional failure remains a significant problem in locally advanced anal cancer patients receiving concurrent chemo radiation therapy. Radiation therapy dose escalation in high risk patients (T3/4 or node positive) will be tested in the forthcoming ACT5 arm of the prospective UK PLATO trial, delivering a simultaneous integrated dose escalating boost of either 58.8 or 61.6 Gy to both primary tumor and positive nodes. Nodal clinical target volume (CTV) – planning target volume (PTV) margin is reduced to 5mm with mandated cone beam computed tomography (CBCT). We aim to demonstrate that ACT5 dose escalation is achievable whilst maintaining acceptable normal tissue toxicity. Advanced (T4 N3+) clinical cases were replanned with dose escalation by two experienced VMAT planners. Doses to organs at risk (OAR) were compared to original clinical plan produced per current UK national guidance (Small Bowel constraint D200, 150, 20cc and 5cc, <30, 35, 45 and 50 Gy respectively; Genitalia D50, 35 and 5%, <20, 30 and 50 Gy respectively; Bladder D50, 35 and 5%, <35, 40 and 50 Gy respectively; no constraint for bone marrow dose). Acceptable PTV coverage (D95>95%) was maintained irrespective of OAR dose. Eight dose escalation plans and four standard plans were assessed. Bowel D150-200cc and Genitalia/Bladder D35-50% were no higher in dose escalated plans. D5% Genitalia dose was comparable (within +/- 3 Gy) and D20cc Bowel dose increased only in those cases were there was overlap with the boost dose PTV. D5% Bladder did increase (mean: 56.6 Gy (51.5-62.2 Gy) relative to 53.2 Gy (51.9-55.1 Gy) but it was not statistically significant. Pelvic bone marrow sparing at the crucial 10-15 Gy dose level was comparable or lower between dose escalated and non-dose escalated plans, see Table 1 below.Tabled 1Abstract 2485; Table 1. Average Bone Marrow dose in standard and dose escalated plans.Standard Plan51.8 Gy61.6 GyWhole Pelvic Bone MarrowV1581.776.677.4V1084.683.183.5Iliac Bone MarrowV1565.060.459.7V1069.267.667.3Lower Pelvis Bone MarrowV1595.391.293.7V10100.098.6100.0Lumbosacral Bone MarrowV1577.771.871.6V1081.076.676.0 Open table in a new tab Dose escalation in high risk anal cancer patients is achievable without sacrifice of sparing of OAR. The use of 5mm nodal margin, facilitated by mandated CBCT, results in dose escalation without increased 10-15 Gy pelvic bone marrow irradiation." @default.
- W2528090440 created "2016-10-14" @default.
- W2528090440 creator A5009197248 @default.
- W2528090440 creator A5011655195 @default.
- W2528090440 creator A5015871113 @default.
- W2528090440 creator A5030248496 @default.
- W2528090440 creator A5044857039 @default.
- W2528090440 creator A5045813553 @default.
- W2528090440 creator A5072020207 @default.
- W2528090440 creator A5072788376 @default.
- W2528090440 date "2016-10-01" @default.
- W2528090440 modified "2023-10-14" @default.
- W2528090440 title "Personalized Dose Escalation in Anal Cancer" @default.
- W2528090440 doi "https://doi.org/10.1016/j.ijrobp.2016.06.1089" @default.
- W2528090440 hasPublicationYear "2016" @default.
- W2528090440 type Work @default.
- W2528090440 sameAs 2528090440 @default.
- W2528090440 citedByCount "1" @default.
- W2528090440 countsByYear W25280904402020 @default.
- W2528090440 crossrefType "journal-article" @default.
- W2528090440 hasAuthorship W2528090440A5009197248 @default.
- W2528090440 hasAuthorship W2528090440A5011655195 @default.
- W2528090440 hasAuthorship W2528090440A5015871113 @default.
- W2528090440 hasAuthorship W2528090440A5030248496 @default.
- W2528090440 hasAuthorship W2528090440A5044857039 @default.
- W2528090440 hasAuthorship W2528090440A5045813553 @default.
- W2528090440 hasAuthorship W2528090440A5072020207 @default.
- W2528090440 hasAuthorship W2528090440A5072788376 @default.
- W2528090440 hasBestOaLocation W25280904401 @default.
- W2528090440 hasConcept C126838900 @default.
- W2528090440 hasConcept C2989005 @default.
- W2528090440 hasConcept C509974204 @default.
- W2528090440 hasConcept C71924100 @default.
- W2528090440 hasConceptScore W2528090440C126838900 @default.
- W2528090440 hasConceptScore W2528090440C2989005 @default.
- W2528090440 hasConceptScore W2528090440C509974204 @default.
- W2528090440 hasConceptScore W2528090440C71924100 @default.
- W2528090440 hasIssue "2" @default.
- W2528090440 hasLocation W25280904401 @default.
- W2528090440 hasLocation W25280904402 @default.
- W2528090440 hasOpenAccess W2528090440 @default.
- W2528090440 hasPrimaryLocation W25280904401 @default.
- W2528090440 hasRelatedWork W141524600 @default.
- W2528090440 hasRelatedWork W1841185769 @default.
- W2528090440 hasRelatedWork W2021771973 @default.
- W2528090440 hasRelatedWork W2022944059 @default.
- W2528090440 hasRelatedWork W2048191766 @default.
- W2528090440 hasRelatedWork W2070138482 @default.
- W2528090440 hasRelatedWork W2155887765 @default.
- W2528090440 hasRelatedWork W2168923614 @default.
- W2528090440 hasRelatedWork W2384708512 @default.
- W2528090440 hasRelatedWork W2428341374 @default.
- W2528090440 hasVolume "96" @default.
- W2528090440 isParatext "false" @default.
- W2528090440 isRetracted "false" @default.
- W2528090440 magId "2528090440" @default.
- W2528090440 workType "article" @default.